Apheresis Column Ligand Leaching Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current apheresis technologies face challenges in effectively removing soluble TNF-alpha receptors (sTNF-Rs) from blood without leaching column materials into the bloodstream, leading to variability and side effects, which complicates the therapeutic approach for cancer treatment.
Innovation Solution
A column with beads of specific diameter and a ligand coupled to the beads, selected to bind to sTNF-Rs, is used to maintain a flow velocity below a threshold, preventing ligand leaching and ensuring efficient removal of sTNF-Rs from the blood, thereby enhancing TNF-alpha activity against neoplastic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If apheresis technology is used to remove sTNF-Rs from blood, then the removal of inhibitory molecules is achieved, but leaching of column materials into the bloodstream occurs causing side effects and complications
Solution Approach 1:
The patent introduces a specific ligand as an intermediary substance that mediates between the column and the blood components. This ligand is designed to selectively bind to sTNF-Rs while being firmly attached to the column matrix, serving as a mediator that achieves the therapeutic goal without causing harmful leaching effects. The ligand acts as a controlled interface that enables specific removal of target molecules while preventing unwanted column material release.
Solution Approach 2:
The patent modifies key parameters of the apheresis system, including the chemical structure and binding characteristics of the ligand, the flow rate through the column, and the composition of the column matrix. By optimizing these parameters, the system achieves effective sTNF-R removal while maintaining ligand stability and preventing leaching. The controlled flow rate parameter is particularly important in balancing removal efficiency with ligand retention.
2Quantity of substance
If current apheresis methods are used to remove sTNF-Rs, then some removal effect is achieved, but variability in removal efficiency and side effects occur
Solution Approach 1:
The patent implements a feedback mechanism where the ligand's binding characteristics and the column's performance are continuously optimized based on observed removal efficiency. The system monitors the interaction between ligand and sTNF-Rs, and adjusts operational parameters to maintain consistent performance. This feedback approach reduces variability by adapting to actual removal efficiency in real-time, ensuring reliable therapeutic outcomes.
Solution Approach 2:
The patent segments the column into functional zones with different ligand densities or types, creating a more controlled and predictable removal process. This segmentation allows different portions of the column to handle specific aspects of sTNF-R removal, reducing variability by distributing the removal load evenly and preventing saturation effects that cause inconsistent performance.
3Quantity of substance
If apheresis is used as a therapeutic approach for cancer treatment, then the potential to enhance TNF-alpha activity is achieved, but complications and doubts about practicality arise
Solution Approach 1:
The patent extracts only the essential functional component (sTNF-Rs) from the blood while leaving other blood components intact. This selective extraction approach simplifies the therapeutic mechanism by focusing on removing the specific inhibitory molecules that block TNF-alpha activity, rather than attempting to directly administer TNF-alpha or its analogs. The simplified approach reduces complexity while achieving the desired therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method efficiently removes sTNF-Rs from plasma, providing a positive clinical impact on cancer tumors while avoiding the negative effects of TNF-alpha leaching, and is applicable to other target components and conditions.
Implementation Method 1
a ligand coupled to the bead and selected to bind to the component
Data Source
AI summary
A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.